MedTrace Logo

Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis

NCT04387344 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2020-05-13

No results posted yet for this study

Summary

Cardiac Amyloidosis (CA) is characterized by a long subclinical phase characterized by deposition of amyloid fibrils in atria, valves and walls of ventricles. Longitudinal dysfunction of the left ventricle (LV) with preserved ejection fraction (EF) is the early phase of CA.

Longitudinal dysfunction mainly involves the LV basal and middle segments with less involvement of the distal segments (apical sparing).

Strain echocardiography (STE) measures myocardial deformation. The technique has been shown to be sensitive for early detection of impaired systolic function and for the study of CA. Additionally, cardiac efficiency (myocardial work) can be derived from myocardial strain data analysis.

In the year 2018, "RNA interferences" (patisiran and inotersen) were included in the list of compassionate therapeutic use programs for exclusive use for the treatment of adult patients with hereditary amyloidosis neuropathy. The aim of our study is to evaluate the morpho-functional modifications with RNA interferences.

Conditions

  • Cardiac Amyloidosis

Sponsors & Collaborators

  • Campisi Mariapaola

    collaborator UNKNOWN

  • University of Messina

    lead OTHER

Principal Investigators

  • Gianluca Di Bella, MD · University of Messina, Italy

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-20
Primary Completion
2020-06-30
Completion
2020-12-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387344 on ClinicalTrials.gov